We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 06, 2021

Rivaroxaban Thromboprophylaxis for Gastric/Gastroesophageal Junction Tumors

Research and practice in thrombosis and haemostasis

 

Additional Info

Research and practice in thrombosis and haemostasis
Rivaroxaban Thromboprophylaxis for Gastric/Gastroesophageal Junction Tumors Versus Other Tumors: A Post Hoc Analysis of the Randomized CASSINI Trial
Res Pract Thromb Haemost 2021 Jul 01;[EPub Ahead of Print], JV Mones, MB Streiff, AA Khorana, GA Bendheim, CV Damaraju, P Wildgoose, P Burton, H Riess, GA Soff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading